Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized trial of different tocilizumab doses in severe non-critical COVID-19
2020-001767-86Phase 2Terminated
- Sponsor
- University College Dublin
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University College Dublin. Started Apr 2020; status: terminated.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001767-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001767-86.